Jan Stenvang

Jan Stenvang

Associate Professor


  1. 2007
  2. Published

    Protein kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

    Frankel, Lisa, Lykkesfeldt, A. E., Hansen, J. B. H. & Stenvang, Jan, 2007, In: Breast Cancer Research and Treatment. 104, 2, p. 165-179 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer

    Rasmussen, L. M., Zaveri, N. T., Stenvang, Jan, Peters, R. H. & Lykkesfeldt, A. E., 2007, In: Breast Cancer Research and Treatment. 106, 2, p. 191-203 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT

    Yde, C. W., Frogne, T., Lykkesfeldt, A. E., Fichtner, I., Issinger, O. G. & Stenvang, Jan, 2007, In: Cancer Letters. 256, 2, p. 229-237 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

    Yde, C. W., Gyrd-Hansen, Mads, Lykkesfeldt, A. E., Issinger, O. & Stenvang, Jan, Jun 2007, In: Molecular Cancer Therapeutics. 6, 6, p. 1869-1876 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. 2006
  7. Published

    Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator

    Juncker-Jensen, A., Lykkesfeldt, A. E., Worm, J., Ralfkiær, U., Espelund, U. & Stenvang, Jan, 1 Aug 2006, In: Growth Hormone and IGF Research. 16, 4, p. 224-239 16 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. 2005
  9. Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd)

    Hrdlicka, P. J., Andersen, N. K., Stenvang, Jan, Hansen, F. G., Haselmann, K. F., Nielsen, C. & Wengel, J., 1 Apr 2005, In: Bioorganic & Medicinal Chemistry. 13, 7, p. 2597-621 25 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd)

    Hrdlicka, P. J., Stenvang, Jan & Wengel, J., 2005, In: Nucleosides, nucleotides & nucleic acids. 24, 5-7, p. 397-400 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd)

    Hrdlicka, P. J., Jepsen, J. S., Nielsen, C., Wengel, J. & Stenvang, Jan, 15 Feb 2005, In: Bioorganic & Medicinal Chemistry. 13, 4, p. 1249-60 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. 2004
  13. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.

    Christensen, G. L., Stenvang, Jan, Fog, C. K., Christensen, I. J. & Lykkesfeldt, A. E., 2004, In: Breast Cancer Research and Treatment. p. 53–63

    Research output: Contribution to journalJournal articleResearchpeer-review

  14. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA)

    Stenvang, Jan, Pfundheller, H. M. & Lykkesfeldt, A. E., 2004, In: Oligonucleotides. 14, 2, p. 147-56 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1...4 5 6 7 8 9 Next

ID: 12922